Home » Stocks » FNCH

Finch Therapeutics Group, Inc. (FNCH)

Stock Price: $17.18 USD -0.33 (-1.88%)
Updated Apr 9, 2021 4:00 PM EDT - Market closed
After-hours: $18.00 +0.82 (4.77%) Apr 9, 7:24 PM
Market Cap 809.96M
Revenue (ttm) 7.72M
Net Income (ttm) -39.34M
Shares Out 47.15M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 9
Last Price $17.18
Previous Close $17.51
Change ($) -0.33
Change (%) -1.88%
Day's Open 17.35
Day's Range 16.67 - 17.97
Day's Volume 47,034
52-Week Range 15.26 - 22.50


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...

Other stocks mentioned: AFCG, CNTB, GANX, JWEL, NAPA, OLO, SNCY ...
2 weeks ago - Benzinga

SOMERVILLE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

3 weeks ago - GlobeNewsWire

Finch Therapeutics Group, a Phase 3-ready biotech developing microbiome therapeutics, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

1 month ago - NASDAQ

Finch Therapeutics Group, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About FNCH

Finch Therapeutics Group is a clinical-stage microbiome therapeutics company leveraging our Human-First Discovery platform to develop a novel class of orally administered biological drugs. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis can increase susceptibility to immune disorders, infections, neurological conditions, cancer and other serious diseases. We are developing novel therapeutics designed to deliver mis... [Read more...]

IPO Date
Mar 19, 2021
Mark Smith, Ph.D.
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, FNCH's revenue was $7.72 million, a decrease of -23.98% compared to the previous year's $10.15 million. Losses were -$39.34 million, 89.6% more than in 2019.

Financial Statements